Monday, 21 August 2017

Global Infantile Spasms Therapeutics Market 2017 Study And Analysis Research Report Forecast To 2021

Infantile Spasms Therapeutics Market 2017

About Infantile Spasms Therapeutics
An infantile spasm is a particular type of seizure found in an epilepsy syndrome of infancy and childhood. It is also known as a West syndrome. The onset of infantile spasm is usually found in the first year of life between four months and eight months of age. The condition constitutes 2% of childhood epilepsies and 25% of epilepsies with onset in the first year of life. There are around 2,000-4,000 new cases observed in the US each year. The overall long-term prognosis for infantile spasms patients is poor. It has been found that 50%-70% of infantile spasms patients develop other seizure types and 18%-50% will develop Lennox–Gastaut syndrome (LGS) or other forms of symptomatic generalized epilepsy.

Technavio’s analysts forecast the global infantile spasms therapuetics market to grow at a CAGR of 10.16% during the period 2017-2021.

Covered in this report 
The report covers the present scenario and the growth prospects of the global thoracic surgery market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of infantile spasms therapuetics.

                  
The market is divided into the following segments based on geography: • Americas
• APAC
• EMEA

Technavio's report, Global Infantile Spasms Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors • H. Lundbeck
• Mallinckrodt Pharmaceuticals
• INSYS Therapeutics

Other prominent vendors • Anavex Life Sciences
• Catalyst Pharmaceuticals
• GW Pharmaceuticals
• ORPHELIA Pharma
• Retrophin
• Valerion Therapeutics

Market driver • Major drugs launch expected in 2017-2021
• For a full, detailed list, view our report

Market challenge • Growing usage of seizure management devices, a threat to drug therapies
• For a full, detailed list, view our report

Market trend • Development of devices and smartphone apps to detect seizures and track medications
• For a full, detailed list, view our report

Key questions answered in this report • What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Complete Report Details @ https://www.wiseguyreports.com/reports/872210-global-infantile-spasms-therapeutics-market-2017-2021                                                                                                                                                                                                                                 
Table of Contents     
    
PART 01: Executive summary
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Infantile spasm: Overview
PART 06: Market landscape
• Global infantile spasms therapeutics market
• Five forces analysis
PART 07: Market segmentation by dosage form
• Solid
• Liquid
PART 08: Market segmentation by ROA
• Oral
• Parenteral
PART 09: Geographical segmentation
• Infantile spasms therapeutics market in Americas
• Infantile spasms therapeutics market in EMEA
• Infantile spasms therapeutics market in APAC
PART 10: Market drivers
• Major drugs launch expected in 2017-2021
• Growing scientific advancements in diagnostics
• Special regulatory designations
PART 11: Impact of drivers
PART 12: Market challenges
• Growing usage of seizure management devices, a threat to drug therapies
• Limited patient population
• Moderate pipeline
PART 13: Impact of drivers and challenges
PART 14: Market trends
• Development of devices and smartphone apps to detect seizures and track medications
• Alternate drugs fill the gap
• Reformulation of marketed drugs
PART 15: Vendor landscape
• Competitive scenario
• Other prominent vendors
PART 16: Key vendor analysis
• H. Lundbeck
• Mallinckrodt Pharmaceuticals
• INSYS Therapeutics PART 17: Appendix
• List of abbreviations
PART 18: Explore Technavio
List of Exhibits 

 Continued…….

For accessing accurate and deep understanding and to gain latest insights and key developments in the area of your interest, we also have a list of conferences in which you will be interested in, for more information, cordially check :


For updating knowledge or for thoroughly understanding various terminologies, we also have vast list of seminars for your reference, for more information cordially check :


CONTACT US:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Posted by at
Labels: , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)